Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential for an improved ocular safety profile and therapeutic index compared to other GABA-aminotransferase (GABA-AT) inhibitors Ovid expects to submit an Investigational New Drug (IND) application in 2H 2022 NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developi
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...